ARKG is trading 4.14% higher as biotechnology remains a strong market theme, supported by innovation, obesity-drug demand, and increased dealmaking.
- Healthcare is attracting defensive allocations amid broader market uncertainty, with XLV rising 1.3% on August 7.
- Investors were also positioning around the July U.S. employment report, a key input for Federal Reserve expectations.
- The move appears sector-driven rather than tied to one dominant ARKG holding.